Search clinical trials for: Tamoxifen

Total 398 results

Northwestern University
National Cancer Institute (NCI); BHR Pharma, LLC

Recruiting

Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast

Estrogen Receptor Positive | Ductal Breast Carcinoma In Situ

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate or Z-Endoxifen Hydrochloride in Treating Patients With Locally Advanced or Metastatic, Estrogen Receptor-Positive, HER2-Negative Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7

United States
National Cancer Institute (NCI)

Completed

Lapatinib and Tamoxifen in Treating Patients With Locally Advanced or Metastatic Breast Cancer That Did Not Respond to Previous Tamoxifen

Stage IV Breast Cancer | Recurrent Breast Carcinoma | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor Positive | Progesterone Receptor Positive | Male Breast Carcinoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer

Breast Ductal Carcinoma In Situ | Invasive Breast Carcinoma | Multicentric Breast Carcinoma | Multifocal Breast Carcinoma | Synchronous Bilateral Breast Carcinoma

United States, France, Spain, Canada, Saudi Arabia, Puerto Rico, Korea, Republic of, Ireland, Colombia, Mexico
National Cancer Institute (NCI)
NCIC Clinical Trials Group; Cancer and Leukemia Group B; North Central Cancer... and other collaborators

Active, not recruiting

Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) (TAILORx)

Hormone Receptor Positive | Stage IA Breast Cancer AJCC v7 | Stage IB Breast Cancer AJCC v7 | Stage IIA Breast Cancer AJCC v6 and v7 | Stage IIB Breast Cancer AJCC v6 and v7 | Stage IIIB Breast Cancer AJCC v7 | Breast Adenocarcinoma

United States, Canada, Australia, Puerto Rico, New Zealand, Ireland, Peru, United Kingdom
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Endocrine Therapy in Treating Patients With HER2 Negative, Low Risk Breast Cancer

Stage 0 Breast Cancer | Invasive Breast Carcinoma | Stage IA Breast Cancer | HER2/Neu Negative | Postmenopausal

United States
Oregon Health and Science University
Merck Women's Health Investigator Initiated Studies Program

Completed

Treatment of Unfavorable Bleeding Patterns in Contraceptive Implant Users (Tamoxifen/BTB)

Bleeding | Breakthrough Bleeding | Implants

United States
ETOP IBCSG Partners Foundation
National Cancer Institute (NCI); NCIC Clinical Trials Group; Cancer and Leukemia... and other collaborators

Active, not recruiting

Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer (SOFT)

Recurrent Breast Carcinoma | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Estrogen Receptor Positive Breast Cancer | Progesterone Receptor Positive Tumor

United States, Canada, Switzerland
National Cancer Institute (NCI)
NRG Oncology

Completed

Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer

Recurrent Uterine Corpus Carcinoma | Endometrial Carcinoma | Stage IIIA Uterine Corpus Cancer | Stage IIIB Uterine Corpus Cancer | Stage IVA Uterine Corpus Cancer | Stage IVB Uterine Corpus Cancer | Stage IIIC1 Uterine Corpus Cancer | Stage IIIC2 Uterine Corpus Cancer

United States
Institut Cancerologie de l'Ouest

Active, not recruiting

Preservation of Fertility by Ovarian Stimulation Associated With Tamoxifen, Prior Chemotherapy for Breast Cancer (PRESAGE)

Breast Cancer

France
Northwestern University
National Cancer Institute (NCI)

Completed

4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ

Estrogen Receptor-positive Breast Cancer | Ductal Breast Carcinoma in Situ

United States
Seoul National University Hospital

Active, not recruiting

Higher Dose Preoperative taMOxifen in Premenopausal bREast Cancer Patients (MORE-T)

Hormone Receptor-positive Breast Cancer | Premenopausal Breast Cancer

Korea, Republic of
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer

Ovarian Serous Adenocarcinoma | Primary Peritoneal Serous Adenocarcinoma | Recurrent Ovarian Low Grade Serous Adenocarcinoma | Borderline Ovarian Serous Tumor | Micropapillary Serous Carcinoma | Recurrent Primary Peritoneal Serous Adenocarcinoma

United States, United Kingdom
European Institute of Oncology
Istituto Oncologico Veneto IRCCS; Ente Ospedaliero Ospedali Galliera; Istituto...

Not yet recruiting

Low Dose TamOxifen and LifestylE Changes for bReast cANcer prevenTion (TOLERANT)

Ductal Carcinoma in Situ | RAD51C Gene Mutation | RAD51D Gene Mutation | PALB2 Gene Mutation | Lobular Carcinoma in Situ | ATM Gene Mutation | CDH1 Gene Mutation | CHEK2 Gene Mutation | BRCA Mutation

Italy
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Completed

Tamoxifen Citrate in Treating Patients With Metastatic or Recurrent Breast Cancer

Breast Cancer | Stage IV Breast Cancer

United States, Canada, Peru
National Cancer Center, Korea

Unknown

Decision Aids for Tamoxifen Treatment in Breast Cancer Patients

Breast Cancer
The Methodist Hospital Research Institute
Millennium Pharmaceuticals, Inc.

Completed

TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer (ANETT)

Estrogen Receptor Positive Breast Cancer

United States
Kafrelsheikh University

Not yet recruiting

Combination Therapy With Isotretinoin and Tamoxifen Expected to Provide Complete Protection Against Severe Acute Respiratory Syndrome Coronavirus (Combination)

COVID-19
TYK Medicines, Inc

Recruiting

A Study of TY-302 in Patients With Advanced Solid Tumors

Breast Cancer | Solid Tumor

China
Austrian Breast & Colorectal Cancer Study Group
AstraZeneca

Completed

Randomized Study Comparing Tamoxifen vs. Tamoxifen + Aminoglutethimide in Postmenopausal Receptor-positive Patients

Early-stage Breast Cancer
NSABP Foundation Inc
National Cancer Institute (NCI)

Completed

Tamoxifen Study

Myocardial Ischemia | Heart Diseases | Cardiovascular Diseases | Coronary Disease | Hypertension
Shaanxi Buchang Pharmaceutical Co., Ltd

Unknown

Efficacy and Safety Study of Guanxin Shutong Capsule to Treat Chronic Stable Angina

Angina, Stable

China
AstraZeneca

Completed

ATAC - Arimidex, Tamoxifen Alone or in Combination

Breast Cancer
Sohag University

Not yet recruiting

Maintenance Hormonal Therapy and DLBCL

Diffuse Large B Cell Lymphoma
Samsung Medical Center

Unknown

Sleep and Activity Patterns in Pre-menopausal Breast Cancer Patients on Tamoxifen Using a Wrist-worn Internet of Things Device

Breast Cancer | Sleep Disorder

Korea, Republic of
Bader, Ted, M.D.

Completed

Fourteen Day Safety of Low-Dose Tamoxifen in Patients With Chronic Hepatitis C Who Have Failed Standard Medical Therapy

Chronic Hepatitis C

United States
SOLTI Breast Cancer Research Group
Novartis

Completed

PAM50 HER2-enriched Phenotype as a Predictor of Response to Dual HER2 Blockade in HER2-positive Early Breast Cancer (PAMELA)

Breast Cancer

Spain
Duke University
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Terminated

Effects of Exercise and Improved Nitric Oxide Bioavailability on Arteriovenous Fistula Maturation

End Stage Renal Disease

United States
Institut Cancerologie de l'Ouest

Completed

Biological Response to Tamoxifen (TAM) in Patients With Breast Cancer Non Metastatic RH+ (TAM)

Non Metastatic Breast Cancer

France
Yonsei University
Inje University

Completed

Study of Cytochrome P450 Polymorphisms (CYP2D6, CYP3A4/5 and CYP2C19) in Breast Cancer Patients

Breast Neoplasms | Antineoplastic Agents | Therapeutic Uses | Survival Analysis

Korea, Republic of
Nalagenetics Pte Ltd

Completed

Tamoxifen Dose Adjustment on Indonesian Female ER+ Breast Cancer Patients Based on CYP2D6 Genotype and Endoxifen Levels

ER+ Breast Cancer

Indonesia
University of Nebraska

Not yet recruiting

Chemoprevention With Tamoxifen in Pre-Invasive Pancreas Mucinous Cystic Neoplasms Not Undergoing Immediate Resection (MCN_Tam)

Pancreatic Cyst | Pancreatic Mucinous Cystic Neoplasm

United States
Assiut University

Unknown

Genetic Study of CYP2D6 Enzyme and Therapeutic Drug Monitoring of Tamoxifen

Breast Cancer
National Cancer Institute (NCI)

Completed

A Phase I Study of OncoLAR® (Registered Trademark) (NSC 685403) With/Without Tamoxifen in Patients With Osteosarcoma

Neoplasm Metastasis | Osteosarcoma

United States
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

Clinical Study on Adjuvant Therapy of TQB3616 Combined With Endocrine Therapy Compared With Placebo Combined With Endocrine Therapy in Patients With Breast Cancer

Breast Cancer

China
Pfizer

Completed

A Study To Determine If Coadministration Of Tamoxifen Alters The Extent Or Rate Of Palbociclib (PD-0332991) Absorption Or Elimination In Healthy Male Volunteers

Healthy

United States
Sun Yat-sen University

Completed

Efficacy of High Dose Tamoxifen to Advanced Hormone Receptor-High Expressed Breast Cancer

Breast Cancer Metastatic

China
Zhejiang Cancer Hospital

Completed

Zoladex Plus Tamoxifen in Breast Cancer

Ultrasonography | Lipemia | Endometrium | Mammography | Estrogen

China
Sun Yat-sen University

Not yet recruiting

Study on the Efficacy and Toxicity of Pamiparib Combined With Tamoxifen in the Treatment of Epithelial Ovarian Cancer Patients With Biochemical Recurrence During First-line PARPi Maintenance Therapy

Ovarian Cancer

China
Eli Lilly and Company

Completed

Phase 3 Study of LY353381 Vs Tamoxifen in Women With Locally Advanced or Metastatic Breast Cancer.

Breast Neoplasms

United States, Argentina, Chile, India, Mexico
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Completed

Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer

Breast Cancer

United States
University of Nottingham

Unknown

Tamoxifen in Patients With Oesophageal Cancer

Gastrointestinal Neoplasms | Cancer

United Kingdom
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Withdrawn

Trastuzumab With or Without Tamoxifen in Treating Women With Progressive Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer
Fengxi Su

Unknown

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Breast Cancer Patients in Premenopausal | Estrogen and/or Progesterone Receptor Positive

China
Karolinska University Hospital

Active, not recruiting

Therapeutic Dose Monitoring (TDM) of Tamoxifen

Breast Cancer | Breast Tumors | Breast Carcinoma | Cancer of Breast | Malignant Neoplasm of Breast

Sweden
Incyte Corporation

Terminated

A Phase 2 Study of the IDO Inhibitor Epacadostat Versus Tamoxifen for Subjects With Biochemical-recurrent-only EOC, PPC or FTC Following Complete Remission With First-line Chemotherapy

Ovarian Cancer | Genitourinary (GU) Tumors

Ukraine, United Kingdom, United States, Australia, Canada, Russian Federation
National Institute of General Medical Sciences...
Indiana University School of Medicine

Completed

Tamoxifen Pharmacogenetics and Clinical Effects

Breast Cancer

United States
Oregon Health and Science University

Completed

Tamoxifen to Reduce Unscheduled Bleeding in New Users of the Levonorgestrel-releasing Intrauterine System (LNG-IUS)

Metrorrhagia | Menorrhagia | Medicated Intrauterine Devices

United States
University of Texas Southwestern Medical Center
National Cancer Institute (NCI)

Terminated

Tamoxifen in Preventing Breast Cancer in Women at Increased Risk for Breast Cancer

Breast Cancer

United States
Radboud University Medical Center

Completed

PharmacoKINEtics of TAMoxifen and Its Metabolites in Breast Cancer Patients: the Influence of a Dose Increase in Phenotypic Poor Metabolizers of CYP2D6 (KINETAM) (KINETAM)

Breast Cancer

Netherlands

Search clinical trials for: Tamoxifen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cambodia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations